Albiglutide antidiabetic drugs

Description Results NMA

CV events NaN [NaN; NaN]

CV events ∞ [NaN; ∞]

albiglutide 30mg weekly (n=31)

vs.

placebo (n=52)

8 arms with liraglutide and 1 arm with exenatide twice daily (+1 arm receiving placebo): albiglutide weekly (4, 15, or 30 mg), every 2 weeks (biweekly; 15, 30, or 50 mg), or monthly (50 or 100 mg)

double-blind

Parallel groups

Sample size: 31/52

Primary endpoint:

FU duration: 16 weeks

phase 2

albiglutide 30mg weekly (n=32)

vs.

placebo (n=50)

8 arms with liraglutide and 1 arm with exenatide twice daily (+1 arm receiving placebo): albiglutide weekly (4, 15, or 30 mg), every 2 weeks (biweekly; 15, 30, or 50 mg), or monthly (50 or 100 mg)

double blind

Parallel groups

Sample size: 32/50

Primary endpoint: 0

FU duration: 16 weeks

phase 2

nausea ∞ [NaN; ∞]

vomiting ∞ [NaN; ∞]

diarrhoea ∞ [NaN; ∞]

treatment-emergent adverse events (TEAEs) 2.25 [0.33; 15.27]

albiglutide 15 mg weekly, 30 mg weekly, 50 mg biweekly, and 100 mg monthly (n=32)

vs.

placebo (n=8)

single-blind

Parallel groups

Sample size: 32/8

Primary endpoint: not unique

FU duration: 4 weeks (+5 wk)

phase 2